By Brad Sorensen, CFA, Zacks Research. NurExone Biologic (TSXV:NRX; OTCQB:NRXBF) is developing a product known as ExoPTEN that is designed to treat patients with acute spinal cord injuries, while also conducting preclinical tests for other conditions that ExoPTEN m...
Research
|
December 11, 2024
|
Over the last year, gold is up over 30 per cent, bitcoin is up over US$58K Gold is viewed as the “de facto” hedge or safe haven Bitcoin may offer a more volatile but potentially higher-risk alternative Check out the video fo...
Coreena Robertson
|
November 28, 2024
|
The CO2 markets and emissions trading are among the few winners of the climate conference in Baku. The dynaCERT share should benefit, as the technology company could face a surge of orders in 2025, potentially leading to a revaluation of the stock. Siemens Energy has rece...
Fabian Lorenz
|
November 27, 2024
|
This past week, Canada’s main stock index, the TSX , hovered just shy of a new all-time high, buoyed by rising metal prices. However, the optimism was tempered as markets stuttered in response to renewed fears surrounding geopolitical tensions, particular...
Jonathon Brown
|
November 21, 2024
|
Discover BioVaxys’ innovative DPX™ platform, a cutting-edge lipid-based delivery system transforming immunotherapy. This video explores how the company’s proprietary technology encapsulates diverse bioactive molecules, enhancing and sustai...
Research
|
October 8, 2024
|
The TSX experienced a roller-coaster week, starting with notable losses but ending with a robust rebound, leading to significant gains. This positive shift has supported investor confidence, proving that it is important to stay updated with recent developments. Let&CloseC...
Jonathon Brown
|
August 1, 2024
|
The following is a transcription of the above video, and The Market Online has edited it for clarity . BioVaxys Technology Corp (CSE:BIOV) is a Canadian-based clinical stage biopharmaceutical company focused on improving patient lives with novel immunotherapies. CE...
Lyndsay Malchuk
|
July 30, 2024
|
As we get through the summer holiday season, the typically calmer market environment presents a prime opportunity for investors to evaluate their portfolios and consider new investments. The TSX continues to offer a variety of promising stocks, particularly in energ...
Jonathon Brown
|
July 4, 2024
|
“We are very excited! We are very, very excited!” So says Dr. Monica Perez, who is running the first human trial for a potential new wonder drug being developed by a tiny but well-financed life sciences start-up, NervGen Pharma Corp. ...
Knox Henderson
|
July 2, 2024
|
The past week has been a roller-coaster ride for the TSX . Volatility was the theme as the market saw dramatic rises and falls, influenced by global economic data, corporate earnings and geopolitical developments. In the face of this tumultuous backdrop, three stocks hav...
Jonathon Brown
|
June 27, 2024
|